Keywords
Cervical Cancer
Quadrivalent Vaccine
Immunogenicity
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To investigate the relationship between quadrivalent HPV vaccination (HPV4V) and Pap smear results in adolescent and women aged 9 to 45 years in the municipality of Paranavaí, Paraná, between 2022and 2024. Methods: The study was conducted at a Basic Health Unit (UBS) using secondary data analysis from E-SUS (Strategy – Unified Health System), National Immunization Program Information System (SIPNI), and Cancer Information System (SISCAN). A total of 442 Pap smears were analyzed, covering a local population from the Family Health Strategy. Results: Among the tests analyzed, 432 (97.74%) showed normal results, and 10 (2.26%) showed cytological alterations. Patients over 46 years old were included due to the significant number of altered results. A moderately negative correlation (r = -0.64) was observed between vaccine doses administration and the occurrence of cytological alterations, evidencing the effectiveness of vaccination in preventing precursor lesions of cervical cancer. Conclusion: HPV vaccination demonstrated a positive impact in preventing precursor lesions of cervical cancer. The study reinforces the importance of expanding vaccine coverage and considering broader age groups in immunization strategies.
References
BORNSTEIN J,et al.Three Year Follow-up of 2-Dose Versus 3-Dose HPV Vaccine. Pediatrics, 2021; 147(1).
BRASIL. Condiloma acuminado (Papilomavírus Humano - HPV) [Internet]. Brasília (DF): Ministério da Saúde; 2020. Disponível em: http://www.aids.gov.br/pt-br/publico-geral/o-que-sao-ist/. Acessoem: 25 jul. 2024.
BRUNI L, et al. Global and regional burden of HPV-related diseases and current vaccination coverage: a meta-analysis and modelling study. The Lancet Global Health, 2021; 9(10): e1112-e1123.
CARVALHO AMC DE, et al. HPV vaccine adherence among adolescents: integrative review. Texto e Contexto – Enfermagem, 2019; 28: e20180257.
CARVALHO CF, et al. Cervical Cancer Screening with HPV Testing: Updates on the Recommendation. Revista Brasileira de Ginecologia e Obstetrícia, 2022; 44(3): 264-271.
CARVALHO NS DE, et al. Protocolo Brasileiro para Infecções Sexualmente Transmissíveis 2020: infecção pelo papilomavírus humano (HPV). Epidemiol. Serv. Saúde, Brasília, 2021; 30(esp1): e2020790.
DALPIAZ VG, et al. Barriers to HPV vaccination in Brazil: parental perceptions and structural challenges. Journal of Public Health, 2021; 43(4): 778-784.
FERREIRA, M. DE C. M, et al. Detecção precoce e prevenção do câncer do colo do útero: conhecimentos, atitudes e práticas de profissionais da ESF. Ciência&SaúdeColetiva, v. 27, n. 6, p. 2291–2302, jun. 2022.
GINSBERG GM, et al. Long-term economic evaluation of the HPV vaccination program in Brazil: A dynamic transmission model approach. Vaccine, 2022; 40(33): 4867-4874.
IBGE. Paranavaí - Panorama. Disponível em: https://cidades.ibge.gov.br/brasil/pr/paranavai/panorama. Acesso em: 16 ago. 2024.
MARRARA ÉF, SANTOS LF. Caracterização socioepidemiológica da população acometida pelo HPV e as dificuldades no manejo da doença. Arquivos Médicos dos Hospitais e da Faculdade de Ciências Médicas da Santa Casa de São Paulo, 2021; 66(1): 1-10.
MESOJEDOVAS W, et al. Imunização do HPV no Brasil e propostas para aumento da adesão à campanha de vacinação. Revista de Saúde Pública, 2023; 57: 79.
MIYAJI KT, et al. Avaliação da resposta imune primária e segurança da vacina de HPV quadrivalente em mulheres transplantadas de órgãos sólidos. The BrazilianJournalofInfectiousDiseases, 2022; 26(2): 13.
MINISTÉRIO DA SAÚDE (Brasil). Cobertura vacinal e vigilância epidemiológica das doenças imunopreveníveis: Relatório 2022. Brasília: Ministério da Saúde, 2023. Disponível em: https://www.gov.br/saude/pt-br/assuntos/imunizacoes. Acesso em: 21 out. 2024.
NDUBUISI C, et al. Conhecimento e conscientização sobre a vacinação contra o câncer do colo do útero e o papilomavírus humano entre estudantes universitárias. Prática Familiar Sul-Africana, 2024; 66(1): 8.
PESTANA MH, GAGEIRO JN. Análise de dados para ciências sociais: a complementaridade do SPSS. 6. ed. Lisboa: EdiçõesSílabo, 2014.
PREM K, et al. Global impact and cost-effectiveness of one-dose versus two-dose human pa pillomavirus vaccination schedules: a comparative modelling analysis. BMC. Med, 2023; 21: 313.
RESTREPO J, et al. Acompanhamento de dez anos da vacina contra o papilomavírus humano 9-valente: imunogenicidade, eficácia e segurança. Pediatrics, 2023; 152(4): 1.
SAMPAIO LF, et al. Avaliação da eficácia e durabilidade da Vacina Anti-HPV nos diferentes esquemas vacinais: Uma revisão sistemática. RevistaContexto&Saúde, 2024; 24(48): e13781.
SINGH D, et al. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Global Health, 2023; 11(2): e197-e206.
VILLA LL, RICHTMANN R. Programas de vacinação contra o HPV em países de baixa e média renda: é hora de otimizar cronogramas e recomendações? Jornal de pediatria, 2023; 99(1): 57-56.
WATSON-JONES D, et al. Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial. The Lancet. Global health, 2022; 10(10): e1473–e1484.
WHO. Human Papillomavirus (HPV) vaccines: WHO position paper, 2022 recommendations. World Health Organization, 2022.